Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Divesiran significantly increased the proportion of clinical responders vs placebo in phlebotomy-dependent polycythemia vera.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.